Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824287 | 0.79 | NPC1 (0.49) | CTBP2NPC1HPGDALDH1A1MEN1 | |
| SCHEMBL2824288 | 0.79 | NPC1 (0.49) | CTBP2NPC1HPGDALDH1A1MEN1 | |
| SCHEMBL5259490 | 0.78 | CTBP2 (0.43) | CTBP2NPC1TAAR1HPGDALDH1A1 | |
| SCHEMBL5343945 | 0.78 | P2RX7 (0.36) | MAPTKDM4E | |
| SCHEMBL4917129 | 0.74 | CYP1A2 (0.42) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL23712598 | 0.71 | CTBP2 (0.47) | CTBP2NPC1TAAR1HPGDALDH1A1 | |
| SCHEMBL5792021 | 0.70 | TAAR1 (0.48) | CTBP2NPC1TAAR1HPGDALDH1A1 | |
| SCHEMBL5342931 | 0.69 | HPGD (0.38) | NPC1HPGDALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL216730 | 0.68 | TAAR1 (0.47) | CTBP2NPC1TAAR1HPGDALDH1A1 | |
| Acetonitrile SCHEMBL29126085 | 0.68 | CTBP2 (0.53) | CTBP2HPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | CARROLL WILLIAM A | 2007-10-04 | — | — | US | disclosed |
| US-7241776-B2 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBVIE INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | P2RX2, P2RX1, P2RX7 | CTBP2 1947/4885NPC1 3161/4885TAAR1 198/4885 |
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | P2RX2, P2RX1, P2RX7 | CTBP2 1947/4885NPC1 3161/4885TAAR1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.